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Introduction
First reported by Laskowski in 1961 [1] and further described by Enzinger [2] , epithelioid sarcoma (ES) is a very rare disease representing less than 1% of all sarcomas [3] . Due to its particular pathological aspect, this sarcoma was formerly difficult to diagnose because of confusion with a variety of tumors with similar morphology. ES are currently assessed by tissue biopsy and require examination by an experienced pathologist. . An important component of the diagnostic process of this disease is the demonstration of the loss of INI1 expression by immunohistochemistry [4, 5] ES are classified by two recognized subtypes, the distal type and the less frequent proximal type. Both entities are predominant in young male adults. Distal-type ES has a high tendency to occur in the extremities, especially in the upper limb [6, 7, 8] .
Conversely, proximal-type ES most commonly affect trunk or deep tissue sites and tend to have a more aggressive clinical course. Tumor grading of ES is based on the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system and is considered as a relevant prognostic factor [9, 10, 11] . ES has a high rate of locoregional recurrence after wide resection as well as metastatic spread, with a specific high incidence of synchronous or metachronous distant metastasis [12, 13] . Metastases regularly involve lung and more particularly lymph nodes, representing one of the typical clinical special features of ES [6, 3] . With 5-year survival rates ranging from 55% to 70%, prognosis of ES patients is generally poor but relatively comparable to other soft tissue sarcomas (STS) [14, 15, 12] . Surgical resection with or without radiotherapy is the accepted standard treatment for localized disease [13, 16] . The role of systemic therapies in patients with advanced stage ES is unclear. Only a few retrospective analyses and case reports have assessed the value of systemic treatment [17, 18] . In these studies, the observed median progression-free survival (PFS) ranged from 3 to 9 months and the overall response rate (ORR) varied between 0 to 60% across the diverse drugs and lines. Prospective disease-specific trials with a focus on ES patients are not available. 
Material and methods

Patient population
This study combined clinical data of patients from the EORTC trials 62012 [19] . The phase II 62043 and phase III 62072 PALETTE trials investigated the activity of the tyrosine kinase inhibitor pazopanib in advanced/metastatic STS after failure of standard chemotherapy [20, 21] . The phase II 62091 TRUSTS trial evaluated whether the cytotoxic compound trabectedin given as first line chemotherapy for advanced/metastatic STS improves the outcome of patients as compared to doxorubicin [22] . We used these study populations as the basis for the current subgroup analysis 
Endpoints
The best response was locally assessed per RECIST 1.1 [23] . The objective response rate was defined as the proportion of patients either achieving a PR or CR as best response to treatment. The duration of objective response was determined from first documentation of CR/PR to RECIST progression.
PFS was calculated from the date of evaluation start to the first documentation of progression or death, whichever occurred first. The date of evaluation start was corresponding to the date of randomization for the 62012, 62072 and 62091 trials and the date of registration for the 62043 trial. Overall survival (OS) was calculated from the date of evaluation start to the date of death. Patients without an event were censored at the time of last follow-up.
Statistical analysis
Survival estimates and corresponding 95% confidence intervals (CI) for PFS and OS were generated using the Kaplan-Meier method. Survival curves were reported overall and according to the line of treatment for advanced disease (first line versus second+ line). All statistical analyses were performed using SAS software version 9.4 (SAS Institute).
Results
Patient and tumor characteristics
A total of 1099 patients with advanced STS were entered in the four prospective clinical trials. This included only 27 patients (2.5%) with ES who were found eligible for the current analysis (10 patients from 62012 trial, 4 from 62043, 7 from 62072 and 6 from 62091), illustrating the orphan character of this STS subtype. The diagnosis was based on local pathology in 9 cases and on central review in 18 cases. Baseline tumor and patient characteristics are summarized in Table 1 .
Median age at diagnosis was 50 years (range 19-72 years) and male gender was predominant (63% 
Response to treatment and survival
As shown in (Table 3) .
Overall median OS was 10.8 months (95% CI The response rate to chemotherapy in ES appears to be similar to pooled populations of multiple STS subtypes, ranging from 5% to 25% in the different trials. However, median PFS and OS for ES patients were lower than for STS patients in all trials, which would indicate that even with equivalent response to treatment, ES patients have a worse prognosis than other STS. It can also be noted that a relatively low response rate (1/13, ORR=8%) was observed in patients with doxorubicin-based regimen compared to those with other 1 st line regimens (3/5, ORR=60%).
Although not considered into this analysis, 5 ES patients were randomized to the placebo arm of the 62072 trial (pazopanib versus placebo) and median PFS was 0.9 months (CI 95%: 0.62-1.84) while median OS was 11.5 months (CI 95%: 0.69-N).
No data from prospective trials have been specifically published yet on the role of systemic therapy in ES patients but a Phase II trial investigating tazemetostat, an EZH2
inhibitor, is currently ongoing [24] . This is a single arm trial where enrolled subjects were As a limitation of our study we could not sub-classify the ES cases in this project but we believe that our series included a high proportion of proximal-type ES (older patients, few primary tumors in the upper limb and relatively poor prognosis). We performed additional exploratory survival analyses by differentiating tumors initially situated in extremities (N=13) versus other locations (N=14), expecting a better prognosis for extremity locations as potentially associated with distal-type. However, PFS and OS were nearly equivalent in thes ES populations.
The current standard of care for advanced, inoperable ES remains yet to be defined.
There is a strong need for specific, prospective clinical trials in ES, ideally involving drugs with a good biological rationale in this disease, and ideally such trials should be randomized. Stratification between first and later lines of treatment, and possibly for proximal versus distal type ES may be required.
To conclude, this analysis reinforces the existing knowledge on systemic therapy in this rare type of sarcoma, notably with previously unstudied drugs such as pazopanib. The low number of patients of this study and its retrospective nature remains a limit in formulating definitive clinical conclusions. This is why systemic treatment of ES remains an unmet medical need and basic and translational research as well as clinical testing of agents for this disease in ES-specific trials stands as a high priority for the sarcoma research community. 
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